Analysis
AI & Data
Can spectral flow read immune metabolism? A nine-target panel asks what each signal means
Wishart and colleagues map metabolic proteins across immune subsets and add NAD(P)H autofluorescence, illustrating why expression and metabolic flux are not interchangeable.
Technical Review of Wishart et al., iScience 28:112894 (2025), DOI 10.1016/j.isci.2025.112894. Preclinical methods and mechanistic exploration, not a validated metabolic diagnostic test.
Metabolism has a measurement problem
Immunologists want to know whether a T cell or myeloid cell is changing its energy programme. But an enzyme's abundance does not equal pathway flux. Wishart and colleagues present a spectral-flow approach that pairs conventional immune phenotype markers with a set of protein indicators from several metabolic pathways. The goal is to make multiplexed metabolic phenotyping more accessible with commercial antibodies and a defined validation strategy, while preserving single-cell population identity.
What exactly is in the panel?
The full-text methods describe 12 immune-cell markers and nine metabolic protein targets: GAPDH for glycolysis; IDH2 for the TCA cycle; cytochrome c for electron transport; HIF-1α for hypoxic response; CD98 for amino-acid transport; CPT1A and ACAC in fatty-acid pathways; and Arg1 and iNOS in arginine and nitric-oxide metabolism. Nine targets should not be confused with nine separate functional flux readouts. Most probes were available as conjugated commercial antibodies; CPT1A and ACAC required secondary-antibody steps, which add validation considerations.
Where the validation helps
The investigators evaluated staining and metabolic patterns through established activation models, then analysed lung myeloid and T-cell subsets after intranasal adenoviral CD40L vaccination in mice. The data illustrate different profiles among tissue-resident and infiltrating myeloid populations and T-cell differentiation states. Cellular NAD(P)H autofluorescence offered an additional label-free signal relevant to metabolic state. Autofluorescence can carry information and simultaneously complicate spectral unmixing; its origin and reference model must therefore be documented carefully.
These comparisons generate mechanistic hypotheses; they do not convert antibody fluorescence or autofluorescence intensity into absolute glycolytic rates. Inferring specific metabolic flux generally requires complementary functional measurements and controls.

The analytical chain to inspect
Start with specificity of each metabolic antibody, assay fixation and permeabilisation effects, secondary-antibody background, dynamic range and reproducibility. Confirm single-stained reference quality and sample-specific autofluorescence treatment. Test whether apparent metabolic contrasts survive alternative gating and batch normalisation. If the proposed claim concerns metabolic function rather than target abundance, design independent perturbation or flux measurements that directly address it.
Why this matters beyond discovery
A clinically oriented laboratory could use this as a framework for research assay development, not as an off-the-shelf clinical biomarker panel. Cross-platform adaptation, specimen stability, numerical reference intervals, quantitative precision, clinical populations and intended decision thresholds were not established by this study. Distinguish exploratory pathway-associated phenotypes from validated functional readouts.
Daily Learning Pill
Protein expression, NAD(P)H autofluorescence and pathway flux are related but distinct quantities. The experimental conclusion should never be stronger than the quantity measured.
Primary source: Wishart et al., iScience full text. See CFCM Academy. The figure above is CFCM original educational synthesis, not a reproduction of the publication.